Targets › AQP4
1 program from 1 company in 2 trials: 2 Phase 2; Neurology, Genitourinary; next expected readout Dec 2027.
Forms a water-specific channel. Plays an important role in brain water homeostasis. (UniProt, P55087)
Open in Phaseline: the race on AQP4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bio-Thera Solutions | BAT4406F Anti-AQP4 monoclonal antibody | AQP4 | Phase 2 | Optic Neuromyelitis Spectrum Disease; Minimal Change Disease (MCD) | Dec 2027 |
Optic Neuromyelitis Spectrum Disease (1) Minimal Change Disease (MCD) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.